BlueCrest Capital Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

BlueCrest Capital Management’s Portfolio SBBP Stock Details SBBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-40,240	Closed	-$200K	–	1181
2019 Q1	$200K	Buy	40,240 +11,805	+42%	+$58.1K	0.01%	955
2018 Q4	$127K	Sell	28,435 -74,369	-72%	-$363K	0.01%	733
2018 Q3	$499K	Sell	102,804 -39,456	-28%	-$202K	0.01%	752
2018 Q2	$854K	Buy	+142,260	New	+$1.04M	0.02%	591
2017 Q2	–	Sell	-11,394	Closed	-$54K	–	1176
2017 Q1	$54K	Buy	+11,394	New	+$34.9K	﹤0.01%	699

Other funds holding SBBP

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlueCrest Capital Management's SBBP Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2019, closing a stake of 40,240 shares — an estimated $200K sold.

BlueCrest Capital Management first reported a position in SBBP in Q1 2017 and held it in 5 quarters. The position peaked at $854K in Q2 2018. 58 funds tracked by Wall St. Rank hold SBBP as of Q2 2019.

BlueCrest Capital Management reported no remaining Strongbridge Biopharma plc. position as of Q2 2019 after selling out during the quarter.
BlueCrest Capital Management sold 40,240 Strongbridge Biopharma plc. shares in Q2 2019, an estimated $200K.
BlueCrest Capital Management first reported a position in Strongbridge Biopharma plc. in Q1 2017 and held it in 5 quarters.
BlueCrest Capital Management's Strongbridge Biopharma plc. position peaked at $854K in Q2 2018.
58 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.